Bone

ea0025p1 | Bone

Does preoperative localisation for total parthyroidectomy in patients with renal failure improve outcome?

ea0025p2 | Bone

Influence of age and gender on expression of primary hyperparathyroidism

ea0025p3 | Bone

Evaluation of the association between serotonin and bone mineral density in patients with neuroendocrine tumours

ea0025p4 | Bone

Management of hypovitaminosis D in patients with primary hyperparathyroidism

ea0025p5 | Bone

Risk factors for femoral neck fracture in Indian postmenopausal women (BMD, Vitamin D study and Propensity for a fall)

ea0025p6 | Bone

Effect of age and gender on bone turnover markers: relationships with oestradiol and parathyroid hormone

ea0025p7 | Bone

Vitamin D insufficiency in hyperparathyroidism

ea0025p8 | Bone

Thyrostimulin expression and signalling in the skeleton

ea0025p9 | Bone

Bone mineral density in patients with primary adrenal insufficiency compared to patients with congenital adrenal hyperplasia

ea0025p10 | Bone

Serum 25-OH-vitamin D levels in thalassaemia major

ea0025p11 | Bone

Bone turnover markers in patients on aminobisphosphonate therapy for osteoporosis

ea0025p12 | Bone

Lithium-induced hypercalcaemia: ‘past, present, and future'

ea0025p13 | Bone

What predicts adverse outcomes in untreated primary hyperparathyroidism?

ea0025p14 | Bone

A gene causing autosomal dominant kyphoscoliosis in an N-ethyl-N-nitrosourea (ENU) mutagenised mouse model is located on a 5 Mb interval on mouse chromosome 4 band A3

ea0025p15 | Bone

Parathyroid hormone concentrations in proton pump inhibitor induced hypomagnesaemia

ea0025p16 | Bone

Radius bone loss with ageing assessed by high-resolution peripheral computed tomography differs in men and women

ea0025p17 | Bone

A 5′-untranslated region mutation of the growth and differentiation factor 5 (Gdf5) gene increases expression and is associated with decreased urinary excretion of the cartilage degradation product, CTX-II: relevance to osteoarthritis

ea0025p18 | Bone

The long-term safety and efficacy of zoledronic acid in the treatment of osteoporosis: a 3-year, randomized extension to the HORIZON-pivotal fracture trial (PFT)

ea0025p19 | Bone

Cervical cord compression in a patient with Paget's disease and primary hyperparathyroidism: a diagnostic challenge

ea0025p20 | Bone

Localisation studies in primary hyperparathyroidism: our experience

ea0025p21 | Bone

Co-existing sarcoidosis, primary hyperparathyroidism and vitamin D deficiency in a patient with hypercalcaemia

ea0025p22 | Bone

Immobility: a rare cause of hypercalcaemia

ea0025p23 | Bone

Ablation of AMP-activated protein kinase (AMPK) α1 catalytic subunit in mice leads to decreased bone loss after ovariectomy and impaired bone response to intermittent PTH treatment

ea0025p24 | Bone

Management of primary hyperparathyroidism

ea0025p25 | Bone

Comparison of two high dose- bolus vitamin D regimens in women with low vitamin D levels

ea0025p26 | Bone

Endocrine Abstracts

Society for Endocrinology BES 2011

Poster Presentations

Does preoperative localisation for total parthyroidectomy in patients with renal failure improve outcome?

Influence of age and gender on expression of primary hyperparathyroidism

Evaluation of the association between serotonin and bone mineral density in patients with neuroendocrine tumours

Management of hypovitaminosis D in patients with primary hyperparathyroidism

Risk factors for femoral neck fracture in Indian postmenopausal women (BMD, Vitamin D study and Propensity for a fall)

Effect of age and gender on bone turnover markers: relationships with oestradiol and parathyroid hormone

Vitamin D insufficiency in hyperparathyroidism

Thyrostimulin expression and signalling in the skeleton

Bone mineral density in patients with primary adrenal insufficiency compared to patients with congenital adrenal hyperplasia

Serum 25-OH-vitamin D levels in thalassaemia major

Bone turnover markers in patients on aminobisphosphonate therapy for osteoporosis

Lithium-induced hypercalcaemia: ‘past, present, and future'

What predicts adverse outcomes in untreated primary hyperparathyroidism?

A gene causing autosomal dominant kyphoscoliosis in an N-ethyl-N-nitrosourea (ENU) mutagenised mouse model is located on a 5 Mb interval on mouse chromosome 4 band A3

Parathyroid hormone concentrations in proton pump inhibitor induced hypomagnesaemia

Radius bone loss with ageing assessed by high-resolution peripheral computed tomography differs in men and women

A 5′-untranslated region mutation of the growth and differentiation factor 5 (Gdf5) gene increases expression and is associated with decreased urinary excretion of the cartilage degradation product, CTX-II: relevance to osteoarthritis

The long-term safety and efficacy of zoledronic acid in the treatment of osteoporosis: a 3-year, randomized extension to the HORIZON-pivotal fracture trial (PFT)

Cervical cord compression in a patient with Paget's disease and primary hyperparathyroidism: a diagnostic challenge

Localisation studies in primary hyperparathyroidism: our experience

Co-existing sarcoidosis, primary hyperparathyroidism and vitamin D deficiency in a patient with hypercalcaemia

Immobility: a rare cause of hypercalcaemia

Ablation of AMP-activated protein kinase (AMPK) α1 catalytic subunit in mice leads to decreased bone loss after ovariectomy and impaired bone response to intermittent PTH treatment

Management of primary hyperparathyroidism

Comparison of two high dose- bolus vitamin D regimens in women with low vitamin D levels

Audit of local management of hyperparathyroidism and evaluation of vitamin D deficiency in PHPT

BiosciAbstracts